Literature DB >> 14872042

Reversible leukoencephalopathy associated with cerebral amyloid angiopathy.

U Oh1, R Gupta, J W Krakauer, A G Khandji, S S Chin, M S V Elkind.   

Abstract

The authors describe three patients with reversible leukoencephalopathy associated with cerebral amyloid angiopathy (CAA). Rapid progression of neurologic symptoms was followed by dramatic clinical and radiographic improvement. Pathologically, CAA was associated with varying degrees of inflammation ranging from none to transmural granulomatous infiltration. In the appropriate clinical context, the MRI finding of lobar white matter edema with evidence of prior hemosiderin deposition may indicate the presence of a reversible CAA leukoencephalopathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14872042     DOI: 10.1212/01.wnl.0000106951.94624.df

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  25 in total

1.  Cerebral amyloid angiopathy related vasculitis: successful treatment with azathioprine.

Authors:  Sebastian Luppe; Samar Betmouni; Neil Scolding; Alastair Wilkins
Journal:  J Neurol       Date:  2010-07-15       Impact factor: 4.849

2.  Case files of the New York City poison control center: paradichlorobenzene-induced leukoencephalopathy.

Authors:  Stephanie H Hernandez; Sage W Wiener; Silas W Smith
Journal:  J Med Toxicol       Date:  2010-06

3.  Steroid-responsive edema in CAA-related inflammation.

Authors:  Richard Daniëls; Jeroen J G Geurts; Joost C Bot; Wouter J Schonewille; Bob W van Oosten
Journal:  J Neurol       Date:  2009-01-23       Impact factor: 4.849

Review 4.  Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.

Authors:  Reisa A Sperling; Clifford R Jack; Sandra E Black; Matthew P Frosch; Steven M Greenberg; Bradley T Hyman; Philip Scheltens; Maria C Carrillo; William Thies; Martin M Bednar; Ronald S Black; H Robert Brashear; Michael Grundman; Eric R Siemers; Howard H Feldman; Rachel J Schindler
Journal:  Alzheimers Dement       Date:  2011-07       Impact factor: 21.566

5.  Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein.

Authors:  Jianting Miao; Feng Xu; Judianne Davis; Irene Otte-Höller; Marcel M Verbeek; William E Van Nostrand
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

6.  Comparison of cerebrospinal fluid profiles in Alzheimer's disease with multiple cerebral microbleeds and cerebral amyloid angiopathy-related inflammation.

Authors:  Akio Kimura; Masao Takemura; Kuniaki Saito; Nobuaki Yoshikura; Yuichi Hayashi; Naoko Harada; Hiroshi Nishida; Hideto Nakajima; Takashi Inuzuka
Journal:  J Neurol       Date:  2016-12-20       Impact factor: 4.849

7.  Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

Authors:  Margaret M Racke; Laura I Boone; Deena L Hepburn; Maia Parsadainian; Matthew T Bryan; Daniel K Ness; Kathy S Piroozi; William H Jordan; Donna D Brown; Wherly P Hoffman; David M Holtzman; Kelly R Bales; Bruce D Gitter; Patrick C May; Steven M Paul; Ronald B DeMattos
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

8.  [Sporadic cerebral amyloid angiopathy with ischemic leukoencephalopathy and microbleeds. Cause for a rapidly progressive dementia syndrome].

Authors:  J Katchanov; G Bohner; M Könneker; U Kopp; K Izadpanah; E Larmann; R Klingebiel; F van Landeghem; F Masuhr; R Zschenderlein
Journal:  Nervenarzt       Date:  2005-10       Impact factor: 1.214

Review 9.  Steroid responsive encephalopathy in cerebral amyloid angiopathy: a case report and review of evidence for immunosuppressive treatment.

Authors:  Raoul P Kloppenborg; Edo Richard; Marieke E S Sprengers; Dirk Troost; Piet Eikelenboom; Paul J Nederkoorn
Journal:  J Neuroinflammation       Date:  2010-03-09       Impact factor: 8.322

10.  A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Authors:  S Salloway; R Sperling; S Gilman; N C Fox; K Blennow; M Raskind; M Sabbagh; L S Honig; R Doody; C H van Dyck; R Mulnard; J Barakos; K M Gregg; E Liu; I Lieberburg; D Schenk; R Black; M Grundman
Journal:  Neurology       Date:  2009-11-18       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.